Notably, we establish that SLC38A2 expression in tumour cells and cDC1s has reciprocal effects on tumour growth, establishing SLC38A2-mediated glutamine acquisition as an intercellular metabolic checkpoint for controlling anti-tumour immunity. The gene discussed is SLC38A2; the disease is neoplasm.